IDEAYA Hits 1rst Milestone with GSK

 

• Preclinical development milestone achieved in connection with ongoing IND-enabling studies to support evaluation of Pol Theta Helicase Inhibitor DC as combo with niraparib
• Potential to realize preclinical and clinical milestones up to $20 million total for preclinical to early Phase 1 clinical, including up to $10 million aggregate through IND effectiveness
• Targeting first-in-human clinical evaluation of Pol Theta Helicase Inhibitor DC in combination with niraparib in H1 2023 for patients having tumors with HRD

https://www.prnewswire.com/news-releases/ideaya-announces-achievement-of-first-milestone-in-ongoing-collaboration-with-gsk-for-potential-first-in-class-pol-theta-helicase-inhibitor-development-candidate-301613385.html